New drugs for coronary heart disease have been developed in China

There may be accurate and effective drug therapy for coronary heart disease in the elderly The newly developed recombinant adenovirus vector drug for the treatment of ischemic heart disease in China has recently been approved by the national high technology research and development plan (863 plan) and entered into clinical research The drug was developed by the Academy of Military Medical Sciences and Wuhan humanwell Pharmaceutical Group, and has been put into operation Next, the clinical efficacy of recombinant adenovirus hepatocyte growth factor injection (Ad-HGF) will be studied, and phase II clinical trial will be completed and phase III clinical trial will be entered according to the national GMP standard Coronary heart disease (CHD) is a kind of ischemic heart disease It is a common disease in men over 45 years old and women over 65 years old However, the vascular disease of severe patients is easy to become small blood vessels, traditional drug treatment is difficult to work, and can not bear surgery or angioplasty Different from the traditional cardiovascular drugs, recombinant adenovirus vector drugs use gene therapy strategy to induce angiogenesis and form collateral circulation in the ischemic area, so as to improve the blood supply in the ischemic area and achieve scientific and effective treatment.